Wells Fargo
CMPI

Wells Fargo’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Wells Fargo’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33
Closed – – 7989
2022
Q1 		$0 Hold
33
– – ﹤0.01% 8300
2021
Q4 		$0 Hold
33
– – ﹤0.01% 8208
2021
Q3 		$0 Buy
33
+1
+3% +$5 ﹤0.01% 7850
2021
Q2 		$0 Sell
32
-2,823
-99% -$20K ﹤0.01% 7792
2021
Q1 		$35K Buy
2,855
+148
+5% +$2.1K ﹤0.01% 5989
2020
Q4 		$39K Buy
2,707
+1,303
+93% +$16.6K ﹤0.01% 5676
2020
Q3 		$16K Buy
+1,404
New +$18K ﹤0.01% 5815

Wells Fargo's CMPI Position: Q2 2022 in Review

Wells Fargo sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 33 shares.

Wells Fargo first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $39K in Q4 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

  • Wells Fargo reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Wells Fargo sold 33 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022.
  • Wells Fargo first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • Wells Fargo's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $39K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Wells Fargo's 13F filing for Q2 2022, filed 12 Aug 2022.